Alector, Inc. ALEC
Regular-session close
After hours · Nov 19, 4:41 PM ET
- YTD
- +47.44%
- 1 year
- +88.52%
5D -0.22 (-8.73%)
- Market cap
- 342.42M
- Revenue (ttm)
- 61.51M
- Profit margin
- -257.54%
- EPS (ttm)
- 0.37
- Shares out
- 97.93M
- P/E ratio
- 6.22
- Forward P/E
- -1.25
- YTD return
- +47.44%
- 1-year return
- +88.52%
- Volume
- 1.63M
- Avg volume
- 3.31M
- Open
- 2.50
- Previous close
- 2.57
- Day's range
- 2.29 – 2.59
- 52-week range
- 1.14 – 2.72
- Beta
- 0.66
- Analysts
- Buy
- Price target
- 5.51 (+139.7%)
Key statistics
- 50-day average
- 3.81
- 200-day average
- 4.92
- Enterprise value
- -240.41M
- Price / sales
- 2.95
- Price / book
- 1.52
- Revenue growth
- 68.40%
- Free cash flow
- -66.92M
- Total cash
- 457.20M
- Total debt
- 34.64M
- Return on equity
- -112.55%
- Short % of float
- 7.83%
Fundamental scorecard
12 of 25 checks passed on ALEC’s reported financials
12of 25 checks passed
- Value 3 of 5
- Growth 2 of 5
- Profitability 3 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.53 | -0.43 | +0.10 | +18.87% |
| Aug 7, 2024 | Jun 1, 2024 | -0.49 | -0.40 | +0.09 | +18.37% |
| Aug 7, 2024 | Jun 1, 2024 | -0.49 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.48 | -0.38 | +0.10 | +20.83% |
| May 8, 2024 | Mar 1, 2024 | -0.48 | — | — | — |
| Feb 27, 2024 | Dec 1, 2023 | -0.80 | -0.49 | +0.31 | +38.75% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2024 | Stifel | down | Buy | Hold |
| Nov 26, 2024 | Morgan Stanley | down | Equal-Weight | Underweight |
| Nov 26, 2024 | BTIG | main | Buy | Buy |
| Nov 26, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Nov 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 17, 2024 | Cantor Fitzgerald | reit | — | Overweight |
About Alector, Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- alector.com
News
Are Medical Stocks Lagging Alector (ALEC) This Year?
Earnings Estimates Rising for Alector (ALEC): Will It Gain? Alector Q3 EPS $1.11 Beats $(0.23) Estimate, Sales $162.866M Beat $2.678M Estimate
Alector Reports Third Quarter 2026 Financial Results and Provides Business Update
Will Alector (ALEC) Report Negative Q3 Earnings? What You Should Know
Alector Announces Pricing of Underwritten Offering
Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments Transcript
Alector Maps Brain-Delivery Pipeline for Alzheimer's, Parkinson's Therapies
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson's Disease and Other Neurodegenerative Diseases
Your note
Sign in to keep a note on ALEC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GAROFALO ELIZABETH A. | Director | Stock Award(Grant) | Jun 11, 2024 | 61,250 |
| GRASSO MARC | Chief Financial Officer | Sale | Dec 1, 2024 | 330,651 |
| HAMMOND PAULA | Director | Sale | Aug 11, 2024 | 60,209 |
| KENKARE-MITRA SARASWATI | Officer | Sale | Dec 1, 2024 | 565,215 |
| LAVIGNE LOUIS J JR | Director | Stock Award(Grant) | Jun 11, 2024 | 81,261 |
| ROMANO GARY | Officer | Sale | Dec 1, 2024 | 349,283 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.90% | 14,595,014 | 27.00M | Sep 29, 2024 |
| Blackrock Inc. | 9.55% | 9,352,044 | 17.30M | Sep 29, 2024 |
| Vanguard Group Inc | 5.57% | 5,455,727 | 10.09M | Sep 29, 2024 |
| Deep Track Capital, Lp | 4.73% | 4,631,998 | 8.57M | Sep 29, 2024 |
| Morgan Stanley | 4.45% | 4,355,770 | 8.06M | Sep 29, 2024 |
| JP Morgan Chase & Company | 2.79% | 2,728,823 | 5.05M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 3.71% | 3,637,369 | 6.73M | Oct 30, 2024 |
| Fidelity Select Portfolios - Biotechnology | 3.61% | 3,535,753 | 6.54M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.42% | 2,365,571 | 4.38M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.14% | 2,098,341 | 3.88M | Oct 30, 2024 |
| JP Morgan Small Cap Growth Fund | 1.54% | 1,506,611 | 2.79M | Sep 29, 2024 |
| Fidelity Growth Company K6 Fund | 1.30% | 1,268,931 | 2.35M | Oct 30, 2024 |
